- Home
- WLKP vs MNPR Comparison
WLKP vs MNPR Comparison
Compare WLKP & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WLKP | MNPR |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 652.0M | 531.6M |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | WLKP | MNPR |
|---|---|---|
| Price | $18.96 | $74.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $97.83 |
| AVG Volume (30 Days) | 88.3K | ★ 157.4K |
| Earning Date | 10-30-2025 | 11-13-2025 |
| Dividend Yield | ★ 9.95% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.39 | N/A |
| Revenue | ★ $1,133,706,000.00 | N/A |
| Revenue This Year | $3.27 | N/A |
| Revenue Next Year | $13.98 | N/A |
| P/E Ratio | $13.59 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.75 | $20.16 |
| 52 Week High | $25.04 | $105.00 |
Technical Indicators
Market Signals| Indicator | WLKP | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 53.42 | 40.24 |
| Support Level | $18.75 | $83.86 |
| Resistance Level | $19.26 | $91.79 |
| Average True Range (ATR) | 0.42 | 7.60 |
| MACD | 0.17 | -1.19 |
| Stochastic Oscillator | 89.70 | 4.28 |
Price Performance
Historical ComparisonAbout WLKP Westlake Chemical Partners LP Common Units representing limited partner interests
Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.